Provectus Biopharmaceuticals, Inc.
PVCT
$0.075
-$0.0012-1.58%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.33% | 10.67% | 20.39% | -19.21% | -41.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.33% | 10.67% | 20.39% | -19.21% | -41.31% |
| Cost of Revenue | 4.83% | 15.08% | 13.06% | -4.54% | -22.01% |
| Gross Profit | -1.37% | -17.23% | -8.66% | -8.02% | 5.58% |
| SG&A Expenses | 278.42% | 92.20% | -6.91% | -17.43% | -33.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 101.35% | 49.32% | 4.67% | -9.63% | -26.70% |
| Operating Income | -127.33% | -57.95% | -0.32% | 5.92% | 21.02% |
| Income Before Tax | -95.07% | -53.53% | 4.49% | 10.25% | 17.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.07% | -53.53% | 4.49% | 10.25% | 17.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.30% | -53.53% | 4.49% | 10.25% | 17.10% |
| EBIT | -127.33% | -57.95% | -0.32% | 5.92% | 21.02% |
| EBITDA | -128.06% | -58.23% | -0.32% | 5.92% | 21.06% |
| EPS Basic | -93.94% | -52.70% | 4.00% | 10.81% | 17.50% |
| Normalized Basic EPS | -121.21% | -61.54% | -5.88% | 2.86% | 19.51% |
| EPS Diluted | -93.94% | -52.70% | 4.00% | 10.81% | 17.50% |
| Normalized Diluted EPS | -121.21% | -61.54% | -5.88% | 2.86% | 19.51% |
| Average Basic Shares Outstanding | 0.12% | 0.07% | 0.03% | 0.01% | 0.01% |
| Average Diluted Shares Outstanding | 0.12% | 0.07% | 0.03% | 0.01% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |